ServiceNow Just Plunged 18% on Earnings. Is This a Once-in-a-Cycle Buying Opportunity?
π ServiceNow shares plunged roughly 18% after Q1 FY2026 earnings sparked a flurry of price target cuts from Goldman Sachs, Jefferies, Piper Sandler, and others.
π° Q4 FY25 subscription revenue grew 21% year-over-year to $3.466 billion while cRPO rose 25% to $12.85 billion.
π€ Management raised the Now Assist ACV target to $1.5 billion, highlighting strong AI traction despite muted sentiment.
π Goldman Sachs cut its price target to $163 from $188 while maintaining a Buy rating on the company.
π Piper Sandler lowered its target to $140 from $200, citing attractive valuation at 5x EV/2027 revenue.
π KeyBanc kept an Underweight rating and cut its target to $85, citing margin guidance cuts due to acquisitions.
π A 75 bps subscription drag from large on-premise Middle East deals slipping contributed to the negative market reaction.
πΈ The company completed a $7.75 billion Armis acquisition and has a pending Veza deal pending completion.
π ServiceNow's board authorized an additional $5 billion share repurchase in January to support shareholder value.
π Shares are down roughly 45% year-to-date, trading near the low end of analyst consensus targets.
ποΈ The May 4 analyst day is a key upcoming catalyst for management to revisit AI monetization and margin trajectory.
βοΈ Analysts debate the valuation with P/E ratios around 60x despite strong underlying growth metrics.
- Q4 FY25 subscription revenue grew 21% year-over-year to $3.466 billion, demonstrating resilient core business growth.
- cRPO increased 25% to $12.85 billion, indicating strong expansion in customer revenue per user.
- The company generated $2 billion in free cash flow, highlighting robust operational efficiency.
- Management raised the Now Assist ACV target to $1.5 billion, signaling confidence in AI monetization.
- ServiceNow completed a $7.75 billion Armis acquisition and has a pending Veza deal, expanding its platform capabilities.
- The board authorized an additional $5 billion share repurchase in January to return capital to shareholders.
- Most major firms maintained Buy ratings despite price target cuts, suggesting long-term durability.
- Morningstar maintains a fair value estimate of $165.52, well above the current trading price.
- Shares plunged roughly 18% on Thursday after Q1 FY2026 earnings sparked a flurry of price target cuts.
- Large on-premise Middle East deals are slipping, causing a 75 bps subscription drag.
- cRPO guidance came in below consensus expectations, raising concerns about near-term growth momentum.
- The stock is down roughly 45% year-to-date, reflecting significant investor skepticism.
- Integration risk on the Armis and pending Veza deals poses potential execution challenges.